![Osvaldo Flores](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Osvaldo Flores
Geen lopende functies
Vermogen: 4 M $ op 31-05-2024
Profiel
Osvaldo Flores is the founder of Novira Therapeutics LLC, which was founded in 2009.
He held the title of President & Chief Scientific Officer from 2009 to 2015.
Dr. Flores's former job was as President, Chief Executive Officer & Director at Century Therapeutics, Inc. He also held the title of Vice President-Research & Development at Janssen, Inc. (Nebraska) from 2015 to 2017.
Dr. Flores received a doctorate degree from both the University of Medicine & Dentistry of New Jersey and Rutgers State University of New Jersey.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
19-04-2024 | 1 321 719 ( 1.59% ) | 4 M $ | 31-05-2024 |
Eerdere bekende functies van Osvaldo Flores
Bedrijven | Functie | Einde |
---|---|---|
CENTURY THERAPEUTICS, INC. | Algemeen Directeur | 11-04-2023 |
Janssen, Inc. (Nebraska)
![]() Janssen, Inc. (Nebraska) Miscellaneous Commercial ServicesCommercial Services Janssen, Inc. (Nebraska) is a private company based in Lincoln, NE. The company provides legal services. | Corporate Officer/Principal | 01-12-2017 |
Novira Therapeutics LLC
![]() Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Oprichter | 01-12-2015 |
Century Therapeutics, Inc. /Old/
![]() Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Algemeen Directeur | - |
Opleiding van Osvaldo Flores
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Rutgers State University of New Jersey | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CENTURY THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Century Therapeutics, Inc. /Old/
![]() Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
Janssen, Inc. (Nebraska)
![]() Janssen, Inc. (Nebraska) Miscellaneous Commercial ServicesCommercial Services Janssen, Inc. (Nebraska) is a private company based in Lincoln, NE. The company provides legal services. | Commercial Services |
Novira Therapeutics LLC
![]() Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |